XORTX Therapeutics Inc.
TSXV XRTX.V
XORTX Therapeutics Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2023: -128.69%
-
XORTX Therapeutics Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -87.56%, a -598.01% change year over year.
-
XORTX Therapeutics Inc. Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -12.54%.
| Date | Return on Capital Employed (ROCE) | Interest Coverage Ratio | Debt to Equity Ratio | Return on Common Equity |
|---|
| CEO | Dr. Allen Warren Davidoff Ph.D. |
| IPO Date | Nov. 5, 2021 |
| Location | Canada |
| Headquarters | 421 – 7th Avenue SW |
| Employees | 2 |
| Sector | Health Care |
| Industries | |
XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy. The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19. XORTX Therapeutics Inc. is based in Vancouver, Canada.
Past 5 years
USD 5.75
StockViz Staff
January 16, 2025
Any question? Send us an email